BD said its new patient comfort clinical studies surrounding its recently launched Physioject equipment shows less pain when self-injecting.
The device encompasses a pre-filled syringe with a hidden-needle. It is intended for patients suffering from chronic diseases like rheumatoid arthritis, and MS.
Patients using the Physioject scored an average of 6 on the pain scale, instead of 15 – the average for a normal pre-filled syringe.
However when asked the reason for reduced pain, Joel Cotten, European product manager of pharmaceutical systems, said the team could only guess it is psychosomatic.
He added: “The device is a non-medical device, appears more friendly, all the needles are not visible. We can guess this helps to create better comfort. Very frankly, we don’t know exactly why, but we are currently conducting more studies.”
New appointments at biopharma and equipment companies also feature in this week's column.
Plus other people on the move in the pharma industry in this week's column.
People are on the move at Baxter, Merck & Co., Johnson & Johnson, and elsewhere in this...
Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe
UCB has more than drugs in its 2015 pipeline, while BUPA and biotechs hire new recruits.